Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence …

In October 2022, these guidelines were reviewed by an expert work group convened by
ASH. Review included limited searches for new evidence and discussion of the search …

Abstract Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases,
result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic …

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events.
Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based …

Background This guideline addressed VTE prevention in hospitalized medical patients,
outpatients with cancer, the chronically immobilized, long-distance travelers, and those with …

Pulmonary embolism is the third most common cause of death from cardiovascular disease
after heart attack and stroke. Sequelae occurring after venous thromboembolism include …

Venous thromboembolism (VTE) is a serious medical condition associated with significant
morbidity and mortality, and an incidence that is expected to double in the next forty years …

Background The clinically appropriate duration of thromboprophylaxis in hospitalized
patients with acute medical illnesses is unknown. In this multicenter, randomized, double …

While there is a clear clinical benefit of oral anticoagulation in patients with atrial fibrillation
(AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major …